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Abstract
Malaria is one of the most deadly diseases infecting humans. Advances in 
elimination and vector control have reduced the global malaria burden in the past 
decade; however, the emerging threat of drug resistance and suboptimal vaccine 
efficacies threaten global eradication efforts. Unlocking novel drug and vaccine 
targets while simultaneously mitigating spread of resistant strains seems to be the 
need of the hour. Protein-protein interactions (PPIs), an integral part of host-
pathogen cross-talk and parasite survival, have only recently emerged as promis-
ing drug targets. Large PPI networks (interactome) are being developed to better 
our understanding of various parasite biochemical pathways. In this chapter, we 
throw light on several newly characterized protein-protein interactions between 
the host (humans) and parasite (plasmodium) in key processes such as hemoglo-
bin degradation, enzyme regulation, protein export, egress, invasion, and drug 
resistance and further discuss their viability for development as novel chemo-
therapeutic targets.
Keywords: malaria, proteases, drug resistance, protein-protein interactions, host-
parasite interactions, interactome
1. Introduction
Malaria is one of the deadliest diseases to affect humans, with the latest WHO 
reports indicating ~445,000 deaths in 2017 alone [1]. More alarmingly, despite 
decades of advances in controlling the malaria epidemic, death rates caused by 
malaria seem to have plateaued in the past 3 years, indicating drug resistance and 
re-emergence. Drug resistance to the current frontline antimalarials have been 
confirmed by many recent studies and steadily observed over increasing geographic 
coverage [2]. Thus, it is of utmost importance to develop novel antimalarials, with 
different modes of action and distinct targets, if possible in conjunction, to check 
the onslaught of malaria. This chapter looks at such potential scope for antimalarial 
drug development: disruption of protein-protein interactions in the malaria parasite 
Plasmodium, crucial for survival and proliferation.
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2. PPIs: the basics
Protein-protein interactions (PPIs) constitute the fundamental backbone 
required for occurrence of any biological event. They are defined as the residue level 
interactions between either the same protein (dimers, trimers, or other multimers) 
or diverse proteins (protein complexes). These basic interactions are necessary for a 
myriad of functions such as kinase signaling, receptor binding, proteolytic diges-
tion, apoptosis regulation, and antigen-antibody interactions [3, 4]. Disruptions 
in the protein interaction networks (PINs) as a result of PPI inhibition have been 
shown to cause several diseases where either single or multiple biochemical path-
ways are affected [5]. Owing to their fundamental roles in almost every process 
imaginable, PPIs have emerged as attractive therapeutic targets in several diseases. 
Several forms of cancer were also shown to have dysregulated protein interaction 
networks (PINs) [6]. Similarly, PPI disruptions have been observed in several auto-
immune as well as parasitic diseases. Small peptides that infiltrate cellular defenses 
and specifically bind to target structures are already in development. Taken 
together, targeting PPIs though challenging can provide a novel understanding of 
biochemical processes as well as uncover new ways to combat diseases like malaria.
PPIs can be generally categorized into several groups depending on their func-
tion or the type of interactions. They include internal (hot-spots) or external 
(surface), obligate (permanent) or non-obligate (transient), stabilizing or destabi-
lizing, ability to induce conformational changes in either of the partner molecules, 
peptide-protein or peptide-peptide interactions, and contiguous or discontiguous 
epitope binding [7] (Figure 1).
Some types of PPIs such as membrane PPIs can be difficult to characterize. 
While dedicated techniques like the split-ubiquitin membrane yeast two-hybrid 
(MYTH) system were developed to specifically detect membrane protein interac-
tions [8], these techniques are still considered time-consuming and labor-intensive. 
Such bottlenecks make it hard to generate a complete picture of the membrane 
interactome. Even for reliable bioinformatic models for detection of membrane 
Figure 1. 
Categorization of PPIs based on types of interactions. (A) Internal, where the site of interaction lies buried 
inside such as “hot-spots”, (B) external, where proteins interact at the surface, (C) where a peptide could 
induce conformational changes upon binding, (D) interactions can be stabilized or dissociated based on the 
type of cofactor/compound binding, (E) whether the epitope binding is contiguous or not, and (F) if both 
interacting partners are peptides/small molecules.
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PPIs to be developed, there need to be large sets of positive, false-positive, as well 
as negative data to accurately train such models, which are currently unavailable for 
membrane PPIs [9]. Thus, decoding membrane PPIs even through bioinformatic 
approaches remains challenging.
3. PPIs in malaria
Malaria traditionally has been treated using inhibitors which target the broad 
spectrum proteasome offering several advantages as compared to specific protein 
inhibitors. Specific inhibitors had comparatively low efficacy in vivo. Also, inhibi-
tors targeting a specific protein/ligand could potentially inhibit parasite growth 
only in stages when the target proteins are expressed. Broad spectrum antimalarials, 
such as the current frontline drugs artemisinins (ARTs) and their combination ther-
apies (ACTs), target and break down various cellular pathways including but not 
limited to hemozoin formation, DNA repair, and mitochondria machinery, which 
make them highly potent within short exposure times [10, 11]. However, exposure 
to various cellular targets leads to the rapid development of drug resistance. While 
resistance to chloroquine worldwide was observed after ~40 years of continued 
use, resistance to ARTs was achieved in a relatively short span of a decade, from its 
inception in late 1990s to the first reported resistance in 2008 [12]. While this rapid 
emergence resistance was partially attributed to suboptimal drug regimens and 
poor administrative practices, the same could be attributed to earlier drugs as well. 
Thus, compounds that are specific/flexible to the target protein are the need of the 
hour. This section deals with and summarizes current knowledge about crucial PPIs 
in various biochemical pathways of the malaria parasite Plasmodium falciparum.
3.1 Hemoglobin hydrolysis
Hemoglobin hydrolysis is one of the most targeted pathways for treatment as it is 
fundamental for parasite survival and involves numerous proteins [13]. Majority of 
earlier and currently used drugs disrupt multiple protein interactions. Several stud-
ies have been conducted recently that target individual PPIs and design inhibitors 
based on those interactions. Our lab has previously identified a “hot-spot” region 
in falcipains, the principal hemoglobinases of P. falciparum [14]. Falcipains contain 
a pro and a mature domain, with the pro domain bound to and blocking access to 
the active site in the mature domain. The interactions between these two domains, 
termed “hot-spot” interactions, dissociate under acidic conditions and are essential 
for hemoglobinase activity. This specific hot-spot was identified at the interface 
of pro and mature domains in falcipain-2 (FP2) and falcipain-3 (FP3). The study 
further demonstrated that synthetic compounds, NA01 and NA03, specifically 
bound to this hot-spot region and stabilized these interactions. Thus, even in the 
presence of an acidic environment (pH - 5.5), pro-mature domains remained intact, 
rendering them inactive [15].
Falcipains, owing to their crucial role in Hb degradation, are considered as 
attractive chemotherapeutic targets. Several inhibitors were designed based on the 
interactions of the FP2 and the active site inhibitor E64. Molecular dynamics (MD) 
simulations indicated that two sets of residues, namely, recruiter groups A (rgA) 
and B (rgB) (rgA (D170, Q171, C168, G169, A151, and G230); rgB (K76, N77, and 
N81)) of FP2 are primarily involved in the initial binding with E64 about 80% and 
14% of the time, respectively, before finally proceeding to bind with the active site 
residues [16]. Efforts elsewhere have focused on selective inhibition of falcipains 
rather than indiscriminate inhibition including its human host cathepsin isoforms. 
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While the S1 and S3 subsite residues have been conserved across Plasmodium and 
human cysteine proteases, the P2 residue in the S2 pocket in falcipains contained 
an acidic amino acid (Asp234 in FP2 and Glu243 in FP3) as compared to neutral 
residues in cathepsins (Leu209 in Cat-K, Ala215 in Cat-L, and Phe211 in Cat-S). 
A class of peptidomimetic amino-nitrile compounds known to inhibit cysteine 
proteases was further engineered to exploit the P2-region charge differences and 
inhibit falcipains specifically [17, 18].
Falcipains also contain a domain at their C-terminal called the hemoglobin 
binding domain (Hb domain), a β-hairpin loop which protrudes away from the 
active site. Deletion of this 14 amino acid domain ablated the ability of falcipains 
to degrade Hb, thus indicating a necessary role of this domain in Hb capture prior 
to degradation at the active site [19]. Our lab recently published another study that 
identified crucial protease-substrate PPIs within this domain. A functionally con-
served single amino acid position in both falcipains (Glu185 in FP2 and Asp194 in 
FP3) was found to be essential for Hb interactions, with activated falcipain mutants 
unable to degrade Hb even with accessibility to the active site. Molecular docking 
results indicated both the residues interacted with Hb-α as well as Hb-β subunits 
with interactions mediated primarily through this position (Figure 2). A specific 
inhibitor which could target this position could have potential applications in 
arresting the parasite hemoglobin degradome [20].
Hemoglobin degradation as a source for parasite growth was also shown to be 
dependent on the hemoglobin tetramer composition. Children (<5 years) have 
different Hb subunits (HbF, α2γ2) as compared to adults (HbA, α2β2), and malaria 
mortality rates have consistently indicated child mortality to be higher (61% of 
Figure 2. 
Interactions of falcipains (FP2, FP3) with Hb (α, β) chains. A residue level interaction map of the interactions 
between Hb-binding motif of FP2 (green) with Hb α chain (a; red) and Hb β chain (B; orange) of 
hemoglobin. Similarly, a view of interactions between C-terminus Hb-binding motif of FP3 (blue) with Hb α 
chain (C; red) and Hb β chain (D; orange). Bond lengths of interactions have been indicated in angstrom units 
(Å). Adapted and modified from [20].
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deaths in 2017) [20]. The essential amino acid isoleucine (I) was found to be a main 
differentiating factor as it is absent in both α and β chains but present in γ subunit 
and makes up to 99% of encoded proteins in P. falciparum proteome [21]. Thus, 
compounds that interfered with the isoleucine acquiring pathways, such as target-
ing the two P. falciparum isoleucyl tRNA synthetases (IRSs), have been described. 
The compound thiaisoleucine, where γ-methylene of isoleucine was substituted 
by a sulfur atom, was found to potently inhibit cytosolic IRS, while another com-
pound, mupirocin, a known inhibitor of methicillin-resistant S. aureus (MRSA) 
IRS, inhibited the apicoplast-localized IRS [22]. Of the 36 putative aminoacyl tRNA 
synthetases present in P. falciparum, nearly 5 have been targeted with potent inhibi-
tors, and more are being tested [23, 24].
3.2 Invasion/egress
Both invasion and egress are important events in the erythrocytic stage and are 
responsible for the malaria symptoms including chills and fever. The process of 
invasion requires a host of proteins to be secreted from its apical organelles includ-
ing rhoptry bodies and micronemes, among others, and is precisely coordinated. 
The parasite initially aligns the merozoite apical region toward the host erythrocyte 
and forms a tight junction at the apex, progressing as the moving junction (MJ) 
pushes the parasite into the erythrocyte, with the erythrocyte surface forming a 
ring around the engorged parasite, which would later become the parasitophorous 
vacuolar membrane (PVM) [25].
While the process of moving junction (MJ) formation and important play-
ers involved in the process were well elucidated in P. falciparum, the other major 
causative agent of malaria, P. vivax, remains poorly understood, partially owing to 
difficulties in culturing P. vivax in vitro. Recombinant P. vivax rhoptry neck protein 
2 (PvRON2), based on literature evidence of involvement of PfRON2 in MJ forma-
tion and invasion, showed that both rhoptry proteins PvRON2 and PvRON4 bound 
preferentially to CD71-labeled human reticulocytes rather than normocytes [26]. 
More importantly, the cysteine-rich C-terminal PvRON2 region strongly interacts 
with PvAMA1 domains II and III, similar to earlier reports of PfRON2-PfAMA1 
interactions [27].
The P. falciparum genome encodes 10 aspartic proteases termed plasmepsins, a 
few of which including PMIX and PMX have remained functionally uncharacter-
ized until recently. Conditional knockdown (KD) using TetR-aptamer regulators 
inserted at PMIX and PMX loci using CRISPR-Cas9 gene editing tools indicated a 
drastic decrease in parasite that could egress in PMIX-KD and role of PMX-KD in 
both invasion and egress. Further, PMX was found to be involved in the processing 
of a semi-proenzyme PfSUB1 to mature protein, a step crucial in both egress and 
invasion and also in the final processing step of a known egress protein, SERA5 
[28]. Another study was simultaneously published that attempted to inhibit the 
activity of both PfPMIX and PfPMX. A hydroxyl-ethyl-amine (HEA) scaffold-
based compound, 49c, was shown to potently inhibit both the proteases in vitro and 
in vivo at nanomolar concentrations and reiterated the role of these two proteases 
in egress and invasion [29]. MD simulations indicated that the flap tip and hinge 
regions present in both the plasmepsins were very well stabilized by the rigid 
structure of compound 49c, leading to higher-binding free energy as compared to 
control plasmepsin inhibitor pepstatin [30].
For a Plasmodium parasite to successfully invade different types of cells at 
different life stages, it must display multiple families of receptor molecules on its 
surface to perform various functions such as gliding and traversal between hepa-
tocyte cells or other motile functions. To successfully egress from erythrocytes, 
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the parasite expresses a merozoite-thrombospondin-related anonymous protein 
(MTRAP) which interacts with the tetrameric glycolytic enzyme, fructose-
1,6-bisphosphate aldolase, for powering the actomyosin motors required for 
movement [31]. However, continuous detachment and reattachment of these two 
enzymes are required for proper gliding motility. Therefore, compounds have 
been described that specifically stabilize MTRAP-aldolase interactions thereby 
rendering the parasite immotile. Of the 400 Medicines for Malaria Venture’s 
(MMV) Malaria Box inhibitor library, a single compound (C4) was found to 
significantly inhibit hepatocyte invasion and led to abnormal gliding movements 
in a dose-dependent manner. A structure of C4 bound to the TRAP-aldolase 
complex could provide better insight into the key interactions of the inhibitor and 
help design more potent compounds [31].
3.3 Protein export
The protein export element (PEXEL) comprising of the conserved sequence 
RxLxE/Q/D is found in the N-terminus of ~300 proteins bound for export in the 
Plasmodium proteome. The aspartic protease plasmepsin V (PMV) was shown 
to be the sole protease involved in the cleavage of the PEXEL domain at the ER, 
specifically cleaving after the leucine residue (RxL↓xE/D/Q ). The first, third, and 
fifth conserved positions were thoroughly probed for role in protease activity and 
showed that the first Arg and third Leu are essential for PMV recognition and cleav-
age, while the fifth E/Q/D position was shown not to be essential for cleavage but 
for trafficking out of PVM [32]. Owing to the importance of PMV, peptidomimetic 
compounds that resembled PEXEL were developed. While statin-based compounds 
were the traditional inhibitors of aspartic proteases, inhibitors based on HEA 
moiety were also shown to be strong inhibitors of aspartic proteases. A compound 
named LG20 consisted of PEXEL-like motif R-L-[L-HEA-A]-E-A, where the 
L-HEA-A mimics the aspartic protease transition state, while HEA motif is proteo-
lytically uncleavable by PMV. Overall, the compound successfully inhibited PMV 
activity with concentrations in the picomolar range [33].
PfEMP1 is one the most studied exported protein as it is one of the exported in 
abundant quantities to the outer surface and thus is an attractive target along with 
others such as circumsporozoite protein (CSP). Immunoprecipitation (IP) and 
mass spectrometry studies of a GFP-tagged minimal section of PfEMP1 (PfEMP1B) 
identified novel targets in different cellular components including parasitophorous 
vacuole (PV), Maurer’s clefts, the plasmodium translocon of exported proteins 
(PTEX) translocon, and a novel exported protein-interacting complex (EPIC). 
Several new interacting partners including parasitophorous vacuole protein-1 
(PV1), PV2, and exported protein-3 (EXP3) have been identified, all of whom 
localized to the newly described EPIC [34]. Finally, a comprehensive pathway of 
PfEMP1 export has been suggested, where PfEMP1 is initially translocated to the 
ER and then trafficked to PTEX machinery and out of PVM with the aid of EPIC, 
where finally it is received by host erythrocytic chaperonin complex, the TCP-1 ring 
complex (TRiC), and transported to erythrocyte surface [34].
IP assays coupled with truncated-construct interaction assays have helped 
identify few prominent PMV-partner PPIs. The P. falciparum ortholog of sig-
nal peptidase complex 25 (PfSPC25) was found to interact with PMV as well 
as PfSec61 and PfSec62 translocon. Together, the PfSPC25-PfSec61-PfSec62 
interactome along with PMV was found to regulate the entry of the effector 
cargo into the ER [35]. Apart from export, protein-protein interactions dur-
ing autophagy, where different cellular components are engulfed and fused 
with vacuoles or lysozymes, can be considered as important PPI targets. The P. 
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falciparum autophagy-related protein 8 (PfAtg8) upon activation binds to PfAtg3 
through a thioester bond, and this complex promotes the membrane assembly 
for the formation of autophagosomes. Solved crystal structure of the PfAtg3-
PfAtg8 complex identified an additional region, called the A-loop, having very 
low sequence similarity to that of humans, thus providing a new avenue for 
drug development [36]. MD simulations revealed several crucial PPIs including 
H-bonds, van der Walls contacts, and other electrostatic interactions that are 
crucial for their interactions. Crucially, a peptidomimetic compound mimicking 
the PfAtg3 segment WLLP that interacts with PfAtg8 was identified to achieve 
maximum potency [37].
3.4 PPIs mediating drug resistance
The emerging threat of resistance to the current frontline drug artemisinin 
(ART), and its combination therapies (ACTs), is a cause of great concern. The 
mechanism of ART action, though generally agreed to generate free radical spe-
cies which disrupt several essential pathways in the parasite, is highly debated. 
Immunoprecipitation studies with chemically tagged ART analogue (AP1) revealed 
that ART interacts with over a dozen proteins and is predominantly activated by 
free heme rather than free ferrous ions. P. falciparum Kelch 13 (PfK13) was identi-
fied as a key marker of ART resistance in several studies, most notably by Ariey 
et al., 2008 [38]. The studies have identified residues in the six Kelch propeller 
domains that are responsible for crucial protein-protein interactions, with the 
mutants failing to interact with its substrates P. falciparum phosphatidylinositol-
3-phosphate (PfPI3P) [39]. PfPI3P has been shown to be involved in the unfolded 
protein response (UPR) pathway, thus helping the parasite cope with the free 
radical-induced stress (Figure 3). Localization studies indicated the PfK13 to 
co-localize with the P. falciparum erythrocyte membrane protein (PfEMP1) and 
majorly concentrated at various proteostasis system in the parasite including ER, 
cytoplasm, and the UPR. Specifically, PfK13 mutants were shown to elevate the 
PI3P-vesicle production and amplification, and their export throughout the parasite 
and into the infected erythrocyte [40].
Structural analysis and MD simulations of PfK13 indicated the presence of two 
evolutionarily highly conserved domains in the broad-complex, tramtrack, and 
bric à brac (BTB) domain and in the shallow binding pocket formed by the six 
propeller domain repeats. These domains displayed a different electrostatic surface 
potential unlike the rest of the bottom PfK13 face and are rich in highly conserved 
arginine and serine residues. While the BTB domain was shown to be involved in 
the recruitment of a scaffold protein Cullin, the propeller domain pocket binds to 
the substrate molecules for further ubiquitination. MD simulations showed that the 
validated PfK13 markers such as C580Y and R539T mutants induced a significant 
structural destabilization in the shallow pocket region as compared to wild type 
while maintaining the overall structural integrity. Specifically, the C580Y mutant 
disrupted a disulfide bridge (C532-C580) and additional H-bonds created with 
neighboring residues not present in wild type strains. In the case of R539T mutant, 
it was shown to have substantially less H-bond interactions along with a complete 
loss of a salt bridge interaction with E606 while also losing another inter-blade 
H-bond interaction [41]. Overall, these mutants lead to significantly diminished 
levels of functional protein which cause diminished substrate interaction, ulti-
mately promoting the PfPI3P-mediated unfolded protein response pathway. Our 
own group, through Co-IP and mass spectrometric studies, has identified several 
novel proteins including Trx-like mero protein (PF3D7_1104400), pyridoxal kinase 
(PF3D7_0616000), trafficking protein particle complex subunit 3 (TRAPP), and 
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putative (PF3D7_0418500) that interact with PfK13 and could potentially have a 
role in stress-mediated response (Atul et al., 2019, unpublished).
4. PPI inhibition: peptidomimetics and design
While several strategies have been employed for PPI inhibition, bioinformat-
ics-based drug design has been at the forefront to design specific PPI inhibitors. 
Structure-based drug design, where the solved structure of an enzyme in com-
plex either with an inhibitor or a natural substrate was used to design inhibitors, 
was popularized in the 1990s. However, rational design for PPI inhibitors needs 
to overcome some common hurdles such as low proteolytic stability, analyzing 
extensive libraries of candidate molecules, and in some cases low ligand effi-
ciency when compared to standard active site inhibitors. Thus, several strategies 
are employed in modern drug synthesis to overcome these problems. Short 
linear peptides tend to have lower conformational stability; thus cyclization of 
Figure 3. 
Role of PfK13 in mediating ART resistance. In the presence of ART, wild PfK13 binds with PfPI3K, which 
results in PfPI3K ubiquitination and degradation, thus dysregulation of phosphoinositide signaling pathways 
ultimately leading to parasite death, while in ART-resistant strains, mutated PfK13 does not bind to PfPI3K 
initiating PI3P signaling thus promoting parasite survival. Adapted and modified from [39].
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the peptide is preferred which rigidifies the structure in an active configura-
tion. Certain modifications in the backbone of the peptide such as backbone 
extension, side-chain shifting to nitrogen atoms (peptoids), and altering the 
stereochemistry can also be applied. Peptoids can easily fold into helices or 
other structures as they consist of repeated nitrogen-substituted glycine units 
that give an added advantage of mimicking the peptide structure and function. 
Stereochemistry of a compound can be changed by using D-peptides instead of 
L-peptides as they are more susceptible to proteolytic degradation and are one 
of the most common strategies to develop potent bioactive compounds. Another 
modification involves using β-peptides; peptides with amino group bound at 
β-carbon instead of α-carbon for each amino acid, often called as foldamers, 
could confer additional proteolytic stability both in vitro and in vivo. A class of 
oligopeptides (<80 residues in length) called as miniproteins can also be utilized 
as they have a rigid, well-defined three-dimensional structure. The 19 kDa 
fragment of merozoite surface protein 1 (MSP1), the fragment that is finally 
displayed on the merozoite surface after several processing steps, was fused 
along with a glycosylphosphatidylinositol (GPI) tag used to create a miniprotein, 
which was successfully targeted by antibodies specific to the miniprotein and 
inhibited erythrocyte invasion [42]. Substantial effort has been made to develop 
rational strategies in designing PPI inhibitors for target proteins that have no 
well-defined binding site (so-called “hot-spot”) and, thus, have previously been 
considered undruggable (Figure 4).
Figure 4. 
Strategies for improving the potency of PPI inhibitors. Schematic showing the various ways peptides can be 
modified (highlighted in red) to achieve potency or improve bioavailability.
Parasitology Research
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Figure 5. 
Crucial interactions between falcipains and ICPs chagasin and falstatin. (A) Solved structure of FP2 and 
chagasin in that the ICP bound to the active site of falcipain and that (B) three loops BD, DE, and FG are 
involved in this interactions. (C, D) mutagenesis studies indicated that just the BC loop of falstatin was 
sufficient for inhibiting both FP2 (C) and FP3 (D), respectively. Adapted and modified from [44, 45].
As described in the earlier section, Villa et al. designed and synthesized peptidomi-
metics belonging to 1,2,3-triazoles, specifically 1,4-disubstituted 1,2,3-triazoles. These 
compounds mimicked the contacts made by PfAtg3 template structure containing the 
residues W-L-L-P, as this template was shown to have the majority of interactions with 
PfAtg8. Of the four compounds synthesized, compound 2 (C2) exhibited prominent 
inhibition (IC50–3.8 μM) in vitro, while C1 had better inhibitory effects in vivo [37].
Natural inhibitors of proteases are one of the best studies substrate groups in 
malaria as they are highly specific, stable, and reversible. Plasmodium spp. contain 
inhibitors of cysteine proteases (ICPs) and endogenous macromolecular inhibitors, 
which regulate the activity of cysteine proteases. Orthologs of ICPs are also observed 
in other apicomplexan groups such as Trypanosoma cruzi, whose ICP is called as cha-
gasin [43]. Chagasin was shown to potently bind to the active site of both falcipains, 
FP2 and FP3. More importantly, three loop regions termed BC-, DE-, and FG loops 
11
Protein-Protein Interactions in Malaria: Emerging Arena for Future Chemotherapeutics
DOI: http://dx.doi.org/10.5772/intechopen.89217
were shown to be involved in active site inhibition (Figure 5A,B) [44]. However, 
further studies with the P. falciparum ICP, falstatin, indicated that unlike other ICPs, 
just the BC loop was sufficient for falcipain inhibition and that Asn289 of falstatin 
formed stabilizing hydrogen bonds and hydrophobic interactions (Figure 5C,D) [45].
5. Conclusion
Protein-protein interactions play roles of utmost importance in the growth and 
survival of any organism. Thus, focused targeting of such interactions specific to 
parasite can help produce robust and effective drugs. Recent research has indicated 
a renewed interest in targeting PPIs in the field of malaria. Various PPIs in pathways 
essential for parasite survival, erythrocyte invasion/egress, drug resistance, and 
others have been elucidated. These new classes of peptidomimetic compounds 
would form the future defense against an ever-increasing resistant parasite threat. 
Targeting PPIs offers several advantages over active site inhibition as ‘hot-spots’ are 
more flexible as compared to the active site and thus can be more selective in terms 
of drug interactions. In contrary to active site, the interactions at allosteric sites and 
exosites in an enzyme occur away from the active site; thus they tend to fall under 
less drug pressure and are less likely to develop resistance.
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